Tacrine, the initial potent and clinically effective acetylcholinesterase (AChE) inhibitor, secured FDA approval in 1993 for Alzheimer’s disease (AD) treatment. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.